Endothelial IL-1R1 is a critical mediator of EAE pathogenesis

Brain, Behavior, and Immunity

Volumn 25, Issue 1, 2011, Pages 160-167

  Li, Qiming ^a   Powell, Nicole ^a   Zhang, Hao ^a   Belevych, Natalya ^a   Ching, San ^a   Chen, Qun ^a   Sheridan, John ^a   Whitacre, aroline ^a   Quan, Ning ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Blood brain barrier; Cytokine; Interleukin 1; Multiple sclerosis; Pathogenesis

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 23; INTERLEUKIN 7; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD; SPLEEN CELL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, CD45; CELL PROLIFERATION; DNA, COMPLEMENTARY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; GREEN FLUORESCENT PROTEINS; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; INTERLEUKIN-17; INTERLEUKIN-23; MACROPHAGE ACTIVATION; MICE; MYELIN-ASSOCIATED GLYCOPROTEIN; NEUTROPHIL INFILTRATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, INTERLEUKIN-1 TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR CELL ADHESION MOLECULE-1;

EID: 78649322189     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2010.09.009     Document Type: Article

References (38)

1. Ahmed S.T., Mayer A., Ji J.D., Ivashkiv L.B. Inhibition of IL-6 signaling by a p38-dependent pathway occurs in the absence of new protein synthesis. J. Leukoc. Biol. 2002, 72(1):154-162.
2. Badovinac V., Mostarica-Stojkovic M., Dinarello C.A., Stosic-Grujicic S. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J. Neuroimmunol. 1998, 85(1):87-95.
3. Baker A.M., Grekova M.C., Richert J.R. EAE susceptibility in FVB mice. J. Neurosci. Res. 2000, 61(2):140-145.
4. Ban E., Milon G., Prudhomme N., Fillion G., Haour F. Receptors for interleukin-1 (alpha and beta) in mouse brain: mapping and neuronal localization in hippocampus. Neuroscience 1991, 43(1):21-30.
5. Basu A., Krady J.K., Levison S.W. Interleukin-1: a master regulator of neuroinflammation. J. Neurosci. Res. 2004, 78(2):151-156.
6. Bauer J., Berkenbosch F., Van Dam A.M., Dijkstra C.D. Demonstration of interleukin-1 beta in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level. J. Neuroimmunol. 1993, 48(1):13-21.
7. Beekhuizen H., Verdegaal E.M., Blokland I., van Furth R. Contribution of ICAM-1 and VCAM-1 to the morphological changes in monocytes bound to human venous endothelial cells stimulated with recombinant interleukin-4 (rIL-4) or rIL-1 alpha. Immunology 1992, 77(3):469-472.
8. Brosnan C.F., Cannella B., Battistini L., Raine C.S. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995, 45(Suppl. 6):S16-21.
9. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995, 37(4):424-435.
10. Ching S., He L., Lai W., Quan N. IL-1 type I receptor plays a key role in mediating the recruitment of leukocytes into the central nervous system. Brain Behav. Immun. 2005, 19(2):127-137.
11. Ching S., Zhang H., Belevych N., He L., Lai W., Pu X.A., Jaeger L.B., Chen Q., Quan N. Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J. Neurosci. 2007, 27(39):10476-10486.
12. Cho Y., Son H.J., Kim E.M., Choi J.H., Kim S.T., Ji I.J., Choi D.H., Joh T.H., Kim Y.S., Hwang O. Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotox Res. 2009, 16(4):361-371.
13. Constien R., Forde A., Liliensiek B., Grone H.J., Nawroth P., Hammerling G., Arnold B. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 2001, 30(1):36-44.
14. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
15. Dincic E., Zivkovic M., Stankovic A., Obradovic D., Alavantic D., Kostic V., Raicevic R. Association of polymorphisms in CTLA-4, IL-1ra and IL-1beta genes with multiple sclerosis in Serbian population. J. Neuroimmunol. 2006, 177(1-2):146-150.
16. Engelhardt B. The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Curr. Pharm. Des. 2008, 14(16):1555-1565.
17. Engelhardt B., Martin-Simonet M.T., Rott L.S., Butcher E.C., Michie S.A. Adhesion molecule phenotype of T lymphocytes in inflamed CNS. J. Neuroimmunol. 1998, 84(1):92-104.
18. Ericsson A., Liu C., Hart R.P., Sawchenko P.E. Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J. Comp. Neurol. 1995, 361(4):681-698.
19. Furlan R., Bergami A., Brambilla E., Butti E., De Simoni M.G., Campagnoli M., Marconi P., Comi G., Martino G. HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 2007, 14(1):93-98.
20. Hauser S.L., Doolittle T.H., Lincoln R., Brown R.H., Dinarello C.A. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 1990, 40(11):1735-1739.
21. Hubbard A.K., Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic. Biol. Med. 2000, 28(9):1379-1386.
22. Lai A.Y., Todd K.G. Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines. Glia 2006, 53(8):809-816.
23. Martin D., Near S.L. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J. Neuroimmunol. 1995, 61(2):241-245.
24. Motoike T., Loughna S., Perens E., Roman B.L., Liao W., Chau T.C., Richardson C.D., Kawate T., Kuno J., Weinstein B.M., Stainier D.Y., Sato T.N. Universal GFP reporter for the study of vascular development. Genesis 2000, 28(2):75-81.
25. O'Brien K., Fitzgerald D.C., Naiken K., Alugupalli K.R., Rostami A.M., Gran B. Role of the innate immune system in autoimmune inflammatory demyelination. Curr. Med. Chem. 2008, 15(11):1105-1115.
26. Ohtsuki S., Kamiya N., Hori S., Terasaki T. Vascular endothelium-selective gene induction by Tie2 promoter/enhancer in the brain and retina of a transgenic rat. Pharm. Res. 2005, 22(6):852-857.
27. Proescholdt M.G., Chakravarty S., Foster J.A., Foti S.B., Briley E.M., Herkenham M. Intracerebroventricular but not intravenous interleukin-1beta induces widespread vascular-mediated leukocyte infiltration and immune signal mRNA expression followed by brain-wide glial activation. Neuroscience 2002, 112(3):731-749.
28. Schiffenbauer J., Streit W.J., Butfiloski E., LaBow M., Edwards C., Moldawer L.L. The induction of EAE is only partially dependent on TNF receptor signaling but requires the IL-1 type I receptor. Clin. Immunol. 2000, 95(2):117-123.
29. Schlaeger T.M., Bartunkova S., Lawitts J.A., Teichmann G., Risau W., Deutsch U., Sato T.N. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc. Natl Acad. Sci. USA 1997, 94(7):3058-3063.
30. Stromnes I.M., Goverman J.M. Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 2006, 1(4):1810-1819.
31. Sutton C., Brereton C., Keogh B., Mills K.H., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006, 203(7):1685-1691.
32. Tam J., Duda D.G., Perentes J.Y., Quadri R.S., Fukumura D., Jain R.K. Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells. PLoS ONE 2009, 4(3):e4974.
33. Theien B.E., Vanderlugt C.L., Eagar T.N., Nickerson-Nutter C., Nazareno R., Kuchroo V.K., Miller S.D. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 2001, 107(8):995-1006.
34. Tsukada N., Miyagi K., Matsuda M., Yanagisawa N., Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J. Neurol. Sci. 1991, 104(2):230-234.
35. Vajkoczy P., Laschinger M., Engelhardt B. Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J. Clin. Invest. 2001, 108(4):557-565.
36. Warabi Y. Role of IL-1 and potential therapies in multiple sclerosis. Drug Discovery Today 2007, 4(1):19-24.
37. Weller R.O., Engelhardt B., Phillips M.J. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol. 1996, 6(3):275-288.
38. Xiao B.G., Bail X.F., Zhang G.X., Hedlund G., Link H. Linomide-mediated protection of oligodendrocytes is associated with inhibition of nitric oxide production and IL-1beta expression in Lewis rat glial cells. Neurosci. Lett. 1998, 249(1):17-20.